Published in N Engl J Med on January 24, 2013
Rapid bacterial whole-genome sequencing to enhance diagnostic and public health microbiology. JAMA Intern Med (2013) 2.52
New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother (2013) 1.47
Selective chemical inhibition of agr quorum sensing in Staphylococcus aureus promotes host defense with minimal impact on resistance. PLoS Pathog (2014) 1.39
The 10 largest public and philanthropic funders of health research in the world: what they fund and how they distribute their funds. Health Res Policy Syst (2016) 1.30
Whole-genome sequencing to control antimicrobial resistance. Trends Genet (2014) 1.25
The FDA reboot of antibiotic development. Antimicrob Agents Chemother (2013) 1.22
Comparison of sputum and nasopharyngeal aspirate samples and of the PCR gene targets lytA and Spn9802 for quantitative PCR for rapid detection of pneumococcal pneumonia. J Clin Microbiol (2013) 1.09
Local inflammation exacerbates the severity of Staphylococcus aureus skin infection. PLoS One (2013) 0.99
Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance. Front Microbiol (2013) 0.99
The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett. Clin Infect Dis (2014) 0.97
Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano Lett (2015) 0.97
Novel approaches are needed to develop tomorrow's antibacterial therapies. Am J Respir Crit Care Med (2015) 0.95
The value of single-pathogen antibacterial agents. Nat Rev Drug Discov (2013) 0.95
Multiple broad-spectrum Beta-lactamase targets for comprehensive surveillance. J Clin Microbiol (2013) 0.93
Childhood infections, antibiotics, and resistance: what are parents saying now? Clin Pediatr (Phila) (2013) 0.91
Epidemiology of multi-drug resistant organisms in a teaching hospital in oman: a one-year hospital-based study. ScientificWorldJournal (2014) 0.90
Impact of Environmental Cues on Staphylococcal Quorum Sensing and Biofilm Development. J Biol Chem (2016) 0.90
The Ethical Significance of Antimicrobial Resistance. Public Health Ethics (2015) 0.90
Antibiotic judo: working gently with prescriber psychology to overcome inappropriate use. JAMA Intern Med (2014) 0.89
"Airborne assault": a new dimension in Acinetobacter baumannii transmission*. Crit Care Med (2013) 0.88
The role of antibiotics in the prevention of post-intravitreal anti-VEGF endophthalmitis: primum non nocere! Eye (Lond) (2014) 0.88
Anti-endotoxin vaccines: back to the future. Virulence (2013) 0.86
Penetration of GSK1322322 into epithelial lining fluid and alveolar macrophages as determined by bronchoalveolar lavage. Antimicrob Agents Chemother (2013) 0.86
Plasmid-Mediated Antibiotic Resistance and Virulence in Gram-negatives: the Klebsiella pneumoniae Paradigm. Microbiol Spectr (2015) 0.86
ω-Hydroxyemodin limits staphylococcus aureus quorum sensing-mediated pathogenesis and inflammation. Antimicrob Agents Chemother (2015) 0.85
Challenges in Preparation of Cumulative Antibiogram Reports for Community Hospitals. J Clin Microbiol (2015) 0.85
The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria. Curr Opin Infect Dis (2015) 0.85
In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model. Antimicrob Agents Chemother (2014) 0.84
The deadly impact of extreme drug resistance in Acinetobacter baumannii. Crit Care Med (2014) 0.84
Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance. PLoS Comput Biol (2015) 0.83
Flipping the switch: tools for detecting small molecule inhibitors of staphylococcal virulence. Front Microbiol (2014) 0.83
Nanoparticle approaches against bacterial infections. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.83
Factors Influencing Antibiotic-Prescribing Decisions Among Inpatient Physicians: A Qualitative Investigation. Infect Control Hosp Epidemiol (2015) 0.82
Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We're Gonna Need a Bigger Boat". Clin Infect Dis (2016) 0.82
Challenges and future prospects of antibiotic therapy: from peptides to phages utilization. Front Pharmacol (2014) 0.81
Important Complexities of the Antivirulence Target Paradigm: A Novel Ostensibly Resistance-Avoiding Approach for Treating Infections. J Infect Dis (2015) 0.81
Enzyme-responsive polyion complex (PIC) nanoparticles for the targeted delivery of antimicrobial polymers. Polym Chem (2016) 0.81
Use of antibiotics as feed additives: a burning question. Front Microbiol (2014) 0.80
The future of antibiotics. Crit Care (2014) 0.80
Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies. Antimicrob Agents Chemother (2014) 0.80
The impact of antimicrobial resistance and aging in VAP outcomes: experience from a large tertiary care center. PLoS One (2014) 0.80
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (2017) 0.79
Conservative fluid therapy in septic shock: an example of targeted therapeutic minimization. Crit Care (2014) 0.79
Predominance of Lactobacillus spp. Among Patients Who Do Not Acquire Multidrug-Resistant Organisms. Clin Infect Dis (2016) 0.78
Revealing bacterial targets of growth inhibitors encoded by bacteriophage T7. Proc Natl Acad Sci U S A (2014) 0.78
The New Antibiotic Mantra-"Shorter Is Better". JAMA Intern Med (2016) 0.78
Transferrin iron starvation therapy for lethal bacterial and fungal infections. J Infect Dis (2014) 0.78
Leveraging antimicrobial stewardship into improving rates of carbapenem-resistant enterobacteriaceae. Virulence (2016) 0.78
Thirty-minute screening of antibiotic resistance genes in bacterial isolates with minimal sample preparation in static self-dispensing 64 and 384 assay cards. Appl Microbiol Biotechnol (2015) 0.78
A model-guided analysis and perspective on the evolution and epidemiology of antibiotic resistance and its future. Curr Opin Microbiol (2014) 0.78
A Bioengineered Three-Dimensional Cell Culture Platform Integrated with Microfluidics To Address Antimicrobial Resistance in Tuberculosis. MBio (2017) 0.78
Advanced mass spectrometry technologies for the study of microbial pathogenesis. Curr Opin Microbiol (2014) 0.77
Photoantimicrobials-are we afraid of the light? Lancet Infect Dis (2016) 0.77
Injections of Predatory Bacteria Work Alongside Host Immune Cells to Treat Shigella Infection in Zebrafish Larvae. Curr Biol (2016) 0.77
A Conformationally Constrained Cyclic Acyldepsipeptide Is Highly Effective in Mice Infected with Methicillin-Susceptible and -Resistant Staphylococcus aureus. PLoS One (2016) 0.76
Synthesis and evaluation of novel analogues of ripostatins. Chemistry (2014) 0.76
Zinc Finger Nuclease: A New Approach to Overcome Beta-Lactam Antibiotic Resistance. Jundishapur J Microbiol (2016) 0.76
Needle-Free Delivery of Acetalated Dextran-Encapsulated AR-12 Protects Mice from Francisella tularensis Lethal Challenge. Antimicrob Agents Chemother (2016) 0.76
Bioprospecting marine plankton. Mar Drugs (2013) 0.76
The immune response and antibacterial therapy. Med Microbiol Immunol (2014) 0.76
Treatment outcome measures for randomized controlled trials of antibiotic treatment for acute bacterial skin and skin structure infections in the emergency department setting. Int J Emerg Med (2015) 0.75
How to Pitch an Antibiotic Stewardship Program to the Hospital C-Suite. Open Forum Infect Dis (2016) 0.75
Toll-like receptor 9 enhances bacterial clearance and limits lung consolidation in murine pneumonia caused by methicillin resistant Staphylococcus aureus. Mol Med (2016) 0.75
Laser thermal ablation of multidrug-resistant bacteria using functionalized gold nanoparticles. Int J Nanomedicine (2017) 0.75
Novel imidazoline antimicrobial scaffold that inhibits DNA replication with activity against mycobacteria and drug resistant Gram-positive cocci. ACS Chem Biol (2014) 0.75
OM-85 is an immunomodulator of interferon-β production and inflammasome activity. Sci Rep (2017) 0.75
Preparation and antimicrobial evaluation of polyion complex (PIC) nanoparticles loaded with polymyxin B. Eur Polym J (2017) 0.75
RAGE-mediated suppression of IL-10 results in enhanced mortality in a murine model of Acinetobacter baumannii sepsis. Infect Immun (2017) 0.75
An overview of systematic reviews of the use of systemic antimicrobials for the treatment of periodontitis. Br Dent J (2014) 0.75
Implications for directionality of nanoscale forces in bacterial attachment. Biophys Rep (2016) 0.75
Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects. Antimicrob Agents Chemother (2015) 0.75
Synergistic effect of Thymbra spicata L. extracts with antibiotics against multidrug- resistant Staphylococcus aureus and Klebsiella pneumoniae strains. Iran J Basic Med Sci (2016) 0.75
Nursing home nurses' and community-dwelling older adults' reported knowledge, attitudes, and behavior toward antibiotic use. BMC Nurs (2017) 0.75
Antimicrobial therapy in neonatal intensive care unit. Ital J Pediatr (2015) 0.75
Comparison of antibacterial effects between antimicrobial peptide and bacteriocins isolated from Lactobacillus plantarum on three common pathogenic bacteria. Int J Clin Exp Med (2015) 0.75
Macroalgal Endophytes from the Atlantic Coast of Canada: A Potential Source of Antibiotic Natural Products? Microorganisms (2013) 0.75
A computational model to monitor and predict trends in bacterial resistance. J Glob Antimicrob Resist (2015) 0.75
Carbapenem-Resistant Klebsiella pneumoniae Infection in Three New York City Hospitals Trended Downwards From 2006 to 2014. Open Forum Infect Dis (2016) 0.75
Antimicrobial Dendrimeric Peptides: Structure, Activity and New Therapeutic Applications. Int J Mol Sci (2017) 0.75
Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis. Vaccine (2015) 0.75
Factors associated with antibiotic prescriptions for the viral origin diseases in office-based practices, 2006-2012. JRSM Open (2017) 0.75
Developing New Antimicrobial Therapies: Are Synergistic Combinations of Plant Extracts/Compounds with Conventional Antibiotics the Solution? Pharmacogn Rev (2017) 0.75
Targeting quorum sensing signal biosynthesis to fight antibiotic resistant infections: Ambuic acid as a model inhibitor. Antimicrob Agents Chemother (2017) 0.75
Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother (2017) 0.75
The damage-response framework of microbial pathogenesis. Nat Rev Microbiol (2003) 4.07
Antibiotic resistance is prevalent in an isolated cave microbiome. PLoS One (2012) 2.84
Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio (2012) 2.15
White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis (2012) 2.11
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis (2007) 24.91
Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA (2002) 10.40
The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis (2008) 9.57
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis (2005) 8.77
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med (2012) 7.04
Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis (2010) 6.59
Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13
Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis (2011) 5.58
Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis (2003) 5.21
Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis (2013) 4.27
Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med (2008) 3.67
Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med (2004) 3.30
Improvement in the health of HIV-infected persons in care: reducing disparities. Clin Infect Dis (2012) 2.70
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep (2002) 2.70
Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) (2010) 2.67
Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. Clin Infect Dis (2011) 2.49
Rising economic impact of clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol (2008) 2.40
It is time to implement routine, not risk-based, HIV testing. Clin Infect Dis (2005) 2.40
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med (2002) 2.36
Destroying the life and career of a valued physician-scientist who tried to protect us from plague: was it really necessary? Clin Infect Dis (2005) 2.06
Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu Rev Microbiol (2011) 1.94
Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials. Clin Infect Dis (2009) 1.83
Seven ways to preserve the miracle of antibiotics. Clin Infect Dis (2013) 1.63
HIV seropositivity predicts longer duration of stay and rehospitalization among nonbacteremic febrile injection drug users with skin and soft tissue infections. J Acquir Immune Defic Syndr (2008) 1.57
The new Clostridium difficile--what does it mean? N Engl J Med (2005) 1.53
Influenza A (H5N1): will it be the next pandemic influenza? Are we ready? Ann Intern Med (2005) 1.52
Quantitative PCR assay using sputum samples for rapid diagnosis of pneumococcal pneumonia in adult emergency department patients. J Clin Microbiol (2005) 1.41
Antiretroviral therapy where resources are limited. N Engl J Med (2003) 1.27
Human immunodeficiency virus 1 infection, cocaine, and coronary calcification. Arch Intern Med (2005) 1.23
The role of anaerobic bacteria in lung abscess. Clin Infect Dis (2005) 1.20
Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis (2008) 1.19
Pilot study of a web-based antibiotic decision management guide. J Am Coll Surg (2006) 1.13
Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One (2011) 1.12
Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. Clin Infect Dis (2008) 1.11
Decline in microbial studies for patients with pulmonary infections. Clin Infect Dis (2004) 1.11
Anti-infective research and development--problems, challenges, and solutions. Lancet Infect Dis (2007) 1.05
Antibacterial resistance leadership group: open for business. Clin Infect Dis (2014) 1.04
Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis (2012) 1.03
Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors. AIDS Patient Care STDS (2003) 1.01
Is there hope for the prevention of future antimicrobial shortages? Clin Infect Dis (2002) 1.00
Unmet medical need in infectious diseases. Clin Infect Dis (2012) 1.00
Novel approaches are needed to develop tomorrow's antibacterial therapies. Am J Respir Crit Care Med (2015) 0.95
Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin Infect Dis (2012) 0.93
Clostridium difficile: an under-recognized cause of reactive arthritis? Clin Rheumatol (2007) 0.92
Prevalence of diabetes mellitus in biopsy-positive giant cell arteritis. J Neuroophthalmol (2012) 0.91
New drugs for Clostridium difficile infection. Clin Infect Dis (2006) 0.91
Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: prognostic value in adults with early-stage disease. J Infect Dis (2002) 0.89
Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia. Clin Infect Dis (2008) 0.89
Fever control in septic shock: import of microorganisms and antimicrobial therapy. Am J Respir Crit Care Med (2013) 0.88
Pneumonia treatment process and quality. Arch Intern Med (2002) 0.87
Clostridium difficile in a HIV-infected cohort: incidence, risk factors, and clinical outcomes. AIDS (2013) 0.87
Detection of circulating Chlamydophila pneumoniae in patients with coronary artery disease and healthy control subjects. Clin Infect Dis (2009) 0.82
Association between oral fluoroquinolones and retinal detachment. Am J Ophthalmol (2012) 0.81
New guidelines for management of dyslipidemia from IDSA and the ACTG. Hopkins HIV Rep (2004) 0.79
Management of hepatitis C: a review of the NIH Consensus Development Conference. Hopkins HIV Rep (2002) 0.78
The DHHS adult ART guidelines are revised. Hopkins HIV Rep (2005) 0.78
Challenges in the management of serious infections. Clin Infect Dis (2006) 0.78
Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients. JAMA (2002) 0.77
International HIV Workshop on Management of Treatment-Experienced Patients. Hopkins HIV Rep (2002) 0.77
Antibiotic administration in community-acquired pneumonia. Chest (2004) 0.77
Smallpox vaccination and the patient with an organ transplant. Clin Infect Dis (2003) 0.76
Screening for HIV. Ann Intern Med (2005) 0.75
Use of the computer program GIDEON at an inpatient infectious diseases consultation service. Clin Infect Dis (2006) 0.75
Procalcitonin and pulmonary aspiration: another possible interpretation. Crit Care Med (2011) 0.75
USPHS updates occupational HIV post-exposure prophylaxis guidelines. Hopkins HIV Rep (2006) 0.75
Smallpox vaccination and HIV infection. Hopkins HIV Rep (2003) 0.75
DHHS issues adult guideline revisions. Hopkins HIV Rep (2004) 0.75
IDSA POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines. Clin Infect Dis (2017) 0.75
Update on opportunistic infections. Hopkins HIV Rep (2002) 0.75
FDA approves Pegasys and Copegus for hepatitis C in patients with HIV co-infection. Hopkins HIV Rep (2005) 0.75
Selected topics from the 9th Conference on Retroviruses and Opportunistic Infections. HIV Clin Trials (2002) 0.75
Atazanavir: clinical use. Hopkins HIV Rep (2003) 0.75
Panel on clinical practices issues revised adult ART guidelines. Hopkins HIV Rep (2003) 0.75
Report from ICAAC: update on opportunistic infections. Hopkins HIV Rep (2002) 0.75
DHHS issues adult guideline revisions. HIV Clin Trials (2004) 0.75
Testing for competence in HIV care. IAPAC Mon (2003) 0.75
3rd IAS conference: prevention highlights. Hopkins HIV Rep (2005) 0.75
Treatment of opportunistic infections. Hopkins HIV Rep (2004) 0.75